Patient info Search Menu

Ambrisentan Mylan 5 mg film-coated tablets – patient leaflet, side effects, dosage

Updated:
Key facts
Status:
Prescription only (POM)
Medicine strength:
5 mg
Contains active substance:
Similar medicines?:

Patient leaflet - Ambrisentan Mylan 5 mg film-coated tablets

1. What Ambrisentan Mylan is and what it is used for

Ambrisentan Mylan contains the active substance ambrisentan. It belongs to a group of medicines called other antihypertensives (used to treat high blood pressure). It is used to treat pulmonary arterial hypertension (PAH) in adults. PAH is high blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs. In people with PAH, these arteries get narrower, so the heart has to work harder to pump blood through them. This causes people to feel tired, dizzy and short of breath.

Ambrisentan Mylan widens the pulmonary arteries, making it easier for the heart to pump blood through them.

This lowers the blood pressure and relieves the symptoms.

Ambrisentan Mylan may also be used in combination with other medicines used to treat PAH.

2. What you need to know before you take Ambrisentan Mylan

Do not take Ambrisentan Mylan:

  • if you are allergic to ambrisentan or any of the other ingredients of this medicine (listed in section 6).
  • if you are pregnant, if you are planning to become pregnant, or if you could become pregnant because you are not using reliable birth control (contraception). Please read the information under ‘Pregnancy’
  • if you are breast feeding. Read the information under ‘Breast-feeding’
  • if you have liver disease. Talk to your doctor, who will decide whether this medicine is suitable for you
  • if you have scarring of the lungs, of unknown cause (idiopathic pulmonary fibrosis).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking this medicine if you have:

  • liver problems
  • anaemia (a reduced number of red blood cells)
  • swelling in the hands, ankles or feet caused by fluid (peripheral oedema)
  • lung disease where the veins in the lungs are blocked (pulmonary veno-occlusive disease).

Your doctor will decide whether

Ambrisentan Mylan is suitable for you. You will need regular blood tests

Before you start taking Ambrisentan Mylan, and at regular intervals while you’re taking it, your doctor will take blood tests to check:

  • whether you have anaemia
  • whether your liver is working properly.

➔ It is important that you have these

regular blood tests for as long as you are taking Ambrisentan Mylan. Signs that your liver may not be working properly include:

  • loss of appetite
  • feeling sick (nausea)
  • being sick (vomiting)
  • high temperature (fever)
  • pain in your stomach (abdomen)
  • yellowing of your skin or the whites of your eyes (jaundice)
  • dark-coloured urine
  • itching of your skin.

If you notice any of these signs:

➔ Tell your doctor immediately. Children and adolescents

Ambrisentan Mylan is not recommended for children and adolescents aged under

18 years as the safety and effectiveness is not known in this age group.

Other medicines and Ambrisentan Mylan

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Your doctor may need to adjust your dose of Ambrisentan Mylan if you start taking cyclosporine A (a medicine used after transplant or to treat psoriasis).

If you’re taking rifampicin (an antibiotic used to treat serious infections) your doctor will monitor you when you first start taking Ambrisentan Mylan.

If you’re taking other medicines used to treat PAH (e.g. iloprost, epoprostenol, sildenafil) your doctor may need to monitor you.

➔ Tell your doctor or pharmacist if you are taking any of these medicines. Pregnancy

Ambrisentan Mylan may harm unborn babies conceived before, during or soon after treatment.

➔ If it is possible you could become pregnant, use a reliable form of birth control (contraception) while you’re taking Ambrisentan Mylan. Talk to your doctor about this.

➔ Don’t take Ambrisentan Mylan if you are pregnant or planning to become pregnant.

➔ If you become pregnant or think that you may be pregnant while you’re taking Ambrisentan Mylan, see your doctor immediately.

If you are a woman who could become pregnant, your doctor will ask you to take a pregnancy test before you start taking Ambrisentan Mylan and regularly while you are taking this medicine.

Breast-feeding

It is not known if Ambrisentan Mylan is transferred to breast milk.

➔ Don’t breast-feed while you’re taking

Ambrisentan Mylan. Talk to your doctor about this.

Fertility

If you are a man taking Ambrisentan Mylan, it is possible that this medicine may lower your sperm count. Talk to your doctor if you have any questions or concerns about this. Driving and using machines

Ambrisentan Mylan may cause side effects, such as low blood pressure, dizziness, tiredness (see section 4), that may affect your ability to drive or use machines. The symptoms of your condition can also make you less fit to drive or use machines.

➔ Don’t drive or use machines if you’re feeling unwell.

Ambrisentan Mylan tablets contains lactose and Allura red (E129)

Ambrisentan Mylan tablets contain small amounts of a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars:

➔ Contact your doctor before taking this medicinal product.

Ambrisentan Mylan tablets contain a colouring agent called Allura red AC Aluminium Lake (E129) which may cause allergic reactions. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

3. How to take Ambrisentan Mylan

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. film-coated tablets Package leaflet: Information for the user

What is in this leaflet

10 mg

5 mg

2415340

[ Page # 1 of 2 ]

Date / Remarks

Date / Remarks

Date / Remarks

Date / Remarks

Date / Remarks Date / Remarks Date / Remarks Date / Remarks 18.03.2021 - KLD SHARED

Date / Remarks

Date / Remarks

dd / mm / yy dd / mm / yy 1 of 2

Die Line

NA

100%

PEPA+

2415340

2415340

2333841

NA

EU/1/19/1368/001-004

400551732, 400552733

Mylan Laboratories Ltd ( Nashik IN)

NA

597564

1

NA

NA

Helvetica Neue LT Pro

NA

9 pt

Update in Labeling

NA

NA

Adobe InDesign CC 9.0

United Kingdom

LIT. (BF) AMBRISENTAN MYLAN TABS (COMMON) GB V2

75079109

75077926

Printed Literature

1

Folded size - 140 x 40 mm

NA

NA

NA

40 gsm ITC Tribeni Paper

How much Ambrisentan Mylan to take

The usual dose of Ambrisentan Mylan is one 5 mg tablet, once a day. Your doctor may decide to increase your dose to 10 mg, once a day.

If you take cyclosporine A, do not take more than one 5 mg tablet of Ambrisentan Mylan once a day.

How to take Ambrisentan Mylan

It is best to take your tablet at the same time each day. Swallow the tablet whole, with a glass of water, do not split, crush or chew the tablet. You can take Ambrisentan Mylan with or without food.

If you take more Ambrisentan Mylan than you should

If you take too many tablets you may be more likely to have side effects, such as headache, flushing, dizziness, nausea (feeling sick), or low blood pressure that could cause light-headedness:

➔ Ask your doctor or pharmacist for

advice if you take more tablets than prescribed.

If you forget to take Ambrisentan Mylan

If you forget a dose of Ambrisentan Mylan, just take the tablet as soon as you remember, then carry on as before.

➔ Don’t take two doses at the same time to make up for a forgotten dose Don’t stop taking Ambrisentan Mylan without your doctor’s advice

Ambrisentan Mylan is a treatment that you will need to keep on taking to control your PAH.

➔ Don’t stop taking Ambrisentan Mylan unless you have agreed this with your doctor.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Conditions you and your doctor need to look out for:

Allergic reactions

This is a common side effect that may affect up to one in 10 people. You may notice a rash or itching and swelling (usually of the face, lips, tongue or throat), which may cause difficulty in breathing or swallowing. Swelling (oedema), especially of the ankles and feet

This is a very common side effect that may affect more than one in 10 people. Heart failure

This is due to the heart not pumping out enough blood, causing shortness of breath, extreme tiredness and swelling in the ankles and legs. This is a common side effect that may affect up to one in 10 people. Anaemia (reduced number of red blood cells)

This is a blood disorder which can cause tiredness, weakness, shortness of breath, and generally feeling unwell. Sometimes this requires a blood transfusion. This is a very common side effect that may affect more than one in 10 people

Hypotension (low blood pressure)

This can cause light-headedness. This is a common side effect that may affect up to one in 10 people.

➔ Tell your doctor straight away if you

get these effects or if they happen suddenly after taking Ambrisentan Mylan. It is important to have regular blood tests, to check for anaemia and that your liver is working properly. Make sure that you have also read the information in section 2 under ‘You will need regular blood tests’ and ‘Signs that your liver may not be working properly’.

Other side effects include

Very common side effects:

  • headache
  • dizziness
  • palpitations (fast or irregular heart-beats)
  • worsening shortness of breath shortly after starting Ambrisentan Mylan
  • a runny or blocked nose, congestion or pain in the sinuses
  • feeling sick (nausea)
  • diarrhoea
  • feeling tired

In combination with tadalafil (another PAH medicine) in addition to the above:

  • flushing (redness of the skin)
  • being sick (vomiting)
  • chest pain/discomfort.

Common side effects:

  • blurry or other changes to vision
  • fainting
  • abnormal blood test results for liver function
  • a runny nose
  • constipation
  • pain in your stomach (abdomen)

    • chest pain or discomfort
    • flushing (redness of the skin)
    • being sick (vomiting)
    • feeling weak
    • nose bleed
    • rash

In combination with tadalafil

In addition to the above, except abnormal blood test results for liver function:

  • ringing in the ears (tinnitus) only when taking the combination treatment. Uncommon side effects:
  • liver injury
  • inflammation of the liver caused by the body’s own defences (autoimmune hepatitis)

In combination with tadalafil

  • sudden hearing loss.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Ambrisentan Mylan

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Ambrisentan Mylan contains

The active substance is ambrisentan. Each film-coated tablet contains 5 mg or 10 mg.

The other ingredients are lactose, see section 2, ‘Ambrisentan Mylan contains lactose’, microcrystalline cellulose (E460i), sodium croscarmellose, magnesium stearate (E570), polyvinyl alcohol part hydrolysed, titanium dioxide (E171), macrogol/PEG, talc (E553b), Allura red (E129), see section 2 ‘Ambrisentan Mylan contains Allura red (E129)’, Indigo carmine (E132) What Ambrisentan Mylan looks like and contents of the pack

Ambrisentan Mylan 5 mg film-coated tablet (tablet) is a pink round biconvex tablet engraved with ‘M’ on one side and ‘AN’ on the other side.

Ambrisentan Mylan 10 mg film-coated tablet (tablet) is a pink, capsule shaped tablet engraved with ‘M’ on one side of the tablet and ‘AN1’ on the other side.

Ambrisentan Mylan is supplied as 5 mg and 10 mg film-coated tablets in packs of 30 tablets and unit dose blister packs of 30x1 tablets or 60 x1 tablets.

Not all pack sizes may be marketed. Marketing Authorisation Holder

Mylan S.A.S.

117 Allée des Parcs

69800 Saint-Priest

France

Manufacturer

Mylan Hungary Kft, Mylan utca 1, 2900 Komárom, Hungary

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: United Kingdom (Northern Ireland)

Mylan IRE Healthcare Limited

Tel: +353 18711600

This leaflet was last revised in December 2020

Detailed information on this medicine is available on the European

Medicines Agency web site:

http://www.ema.europa.eu.

2415340

75079109

[ Page # 2 of 2 ]

Date / Remarks Date / Remarks Date / Remarks Date / Remarks Date / Remarks Date / Remarks Date / Remarks Date / Remarks 18.03.2021 - KLD SHARED

Date / Remarks

Date / Remarks

dd / mm / yy dd / mm / yy 2 of 2

Die Line

NA

100%

PEPA+

2415340

2415340

2333841

NA

EU/1/19/1368/001-004

400551732, 400552733

Mylan Laboratories Ltd ( Nashik IN)

NA

597564

1

NA

NA

Helvetica Neue LT Pro

NA

9 pt

Update in Labeling

NA

NA

Adobe InDesign CC 9.0

United Kingdom

LIT. (BF) AMBRISENTAN MYLAN TABS (COMMON) GB V2

75079109

75077926

Printed Literature

1

Folded size - 140 x 40 mm

NA

NA

NA

40 gsm ITC Tribeni Paper

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk)

Last revision stated in the text: December 2020

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Ambrisentan Mylan 5 mg film-coated tablets

What these facts mean

Prescription needed?? Yes, prescription-only medicine (POM)
Active substance? Ambrisentan
Strength? 5 mg
Pharmaceutical form? Oral tablet
Pink, round, biconvex film-coated tablet with ‘M’ debossed on one side and ‘AN’ on the other, approximately 5.7 mm in diameter.
How is it taken? Oral
Excipients? Lactose, Microcrystalline cellulose (E460i), Croscarmellose sodium, Magnesium stearate (E570), Poly(vinyl alcohol) (partly hydrolysed), Titanium dioxide (E171), Macrogol, Talc (E553b), Allura red AC Aluminium Lake (E129), Indigo Carmine Aluminium Lake (E132).
Pack sizes 30 tablet
Is it available?? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life? 3 years
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC)? Anti-hypertensives, other anti-hypertensives
  1. C Cardiovascular system drugs
    1. C02 Antihypertensives
      1. C02K Other antihypertensives
        1. C02KX Antihypertensives for pulmonary arterial hypertension
          1. C02KX02 ambrisentan
Marketing authorisation? PLGB 04569/2027 (first authorised 21 March 2024)
Marketing authorisation holder? Generics (U.K.) Limited T/A Viatris
Codes? GTIN 5016695925844 · BNF 02050100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.1.0 of 9 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.